Skip to content
Amrutanjan Health Care logo

Amrutanjan Health Care

AMRUTANJAN NSE
₹493.00 3.50 (0.72%)
Market Cap
₹1,425 Cr
P/E
26.41

Amrutanjan Health Care (AMRUTANJAN) share price was ₹493.00 at the 28 Oct 2026 close; market capitalisation ₹1,425 Cr; P/E (TTM) 26.41; sector Healthcare. The share price fell 33.5% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 9.5% year on year to ₹102.97 Cr and net profit fell 47.4% year on year to ₹4.37 Cr (compared with Jun 2025). Promoters held 46.52% of Amrutanjan Health Care in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 51/100 (Average) as of 28 Oct 2026.

Close 28 Oct 2026 ₹493.00 −248.30 −33.50% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹1,425 Cr
P/E (TTM)
26.41
EBITDA
₹36.50 Cr
Return on Equity
18.92%
Debt to Equity
0.01
Book Value
₹128.06
EPS (TTM)
₹18.67
52W High
₹760.15
52W Low
₹476.50

Price-based figures as of 28 Oct 2026, 15:31 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,757.5034.864,21,683 Cr5.050.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,558.5086.752,53,748 Cr15.140.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,557.0071.541,73,334 Cr9.430.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,181.90107.801,17,891 Cr22.240.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,175.5026.161,17,257 Cr4.330.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,335.4034.591,11,463 Cr2.870.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.6032.721,10,321 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Amrutanjan Health Care (this company)
₹493.0026.411,425 Cr3.851.00%18.92%29.24%529 Cr54 Cr
Median 8 companies₹1,561.5534.731,17,574 Cr4.690.72%14.56%18.45%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100. How it works →

As of 2026-10-28
v2.0.0
51 Average
Overall score
Data confidence 100/100

Category scores

Quality Good 58
Returns, margins, earnings quality 22%
Valuation Average 55
Cheap vs sector & own history 24%
Growth Weak 39
Sales & profit trajectory 9%
Financial Health Strong 83
Solvency, leverage, coverage 9%
Momentum Poor 24
Trend strength, vol-adjusted 12%
Ownership Average 50
FII/DII/promoter flows 24%

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 26.7%
  • Company's working capital requirements have reduced from 122 days to 93.8 days

Weaknesses

2
  • The company has delivered a poor sales growth of 8.59% over past five years.
  • Promoter holding has decreased over last 3 years: -4.07%

Technical Indicators

Oscillators

BearishNeutralBullish

Bearish

Bearish
2
Neutral
7
Bullish
0

Overall

BearishNeutralBullish

Bearish

Bearish
12
Neutral
7
Bullish
0

Moving Averages

BearishNeutralBullish

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
12.51% higher than 3Y

change over 1 year

Net Income Growth
38.26% higher than 3Y

change over 1 year

Cash Flow Change
13.01%

change over 1 year

EBITDA Margin Change
15.48%

change over 1 year Operating margin 6.06% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
77.86
99.31
117
127
83.74
110
123
135
94.05
118
141
150
103
Expenses
70.71
92.47
95.42
111
80.19
96.32
99.4
118
85.61
101
116
124
96.73
Operating Profit
7.15
6.84
21.57
16.24
3.55
13.6
23.35
17.7
8.44
16.52
25.17
25.55
6.24
OPM %
9.18%
6.89%
18.44%
12.78%
4.24%
12.37%
19.02%
13.07%
8.97%
14.04%
17.85%
17.06%
6.06%
Other Income
3.69
3.95
3.76
4.95
4.45
4.05
4.36
4.82
4.43
4.3
2.87
-2.88
1.78
Interest
0.02
0.03
0.05
0.05
0.06
0.06
0.06
0.04
0.05
0.05
0.05
0.05
0.04
Depreciation
1.39
1.55
1.58
1.53
1.59
1.65
1.66
1.62
1.53
1.56
1.62
1.61
1.92
PBT
9.43
9.21
23.7
19.61
6.35
15.94
25.99
20.86
11.29
19.21
26.37
21.01
6.06
Tax %
25.56%
25.62%
26.41%
30.34%
27.24%
25.97%
25.93%
27.23%
26.4%
27.33%
26.2%
22.94%
28.05%
Net Profit
7.01
6.85
17.45
13.66
4.62
11.8
19.25
15.18
8.31
13.96
19.45
16.19
4.37
EPS (₹)
2.4
2.37
6.04
4.72
1.6
4.08
6.66
5.25
2.87
4.83
6.73
5.6
1.51
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
154
174
207
220
253
261
333
406
380
421
452
503
511
Expenses
130
143
178
192
222
231
258
326
335
369
394
427
438
Operating Profit
25
32
29
28
31
31
75
80
45
52
58
76
73
OPM %
16%
18%
14%
13%
12%
12%
22%
20%
12%
12%
13%
15%
14%
Other Income
5
6
7
8
7
8
11
15
15
16
18
9
6
Interest
1
0
0
0
0
0
1
1
0
0
0
0
0
Depreciation
2
3
2
3
3
4
4
4
5
6
7
6
7
PBT
26
35
34
33
35
34
82
91
54
62
69
78
73
Tax %
35%
35%
35%
39%
29%
27%
25%
26%
26%
27%
26%
26%
—
Net Profit
17
22
22
20
25
25
61
67
40
45
51
58
54
EPS (₹)
5.86
7.68
7.47
6.84
8.39
8.58
20.93
22.99
13.63
15.55
17.58
20.03
18.67
Div. Payout %
30%
25%
26%
22%
26%
24%
20%
20%
34%
30%
26%
24%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
3
3
3
3
3
3
3
3
3
3
3
3
Reserves
102
118
113
126
143
156
213
262
288
286
324
367
Borrowings
0
0
2
0
0
2
1
1
1
2
2
2
Other Liabilities
25
28
34
38
42
44
57
84
70
77
93
137
Total Liabilities
130
149
152
166
188
205
274
350
362
367
421
509
Fixed Assets
13
22
27
28
26
26
23
28
49
50
49
51
CWIP
4
1
1
0
0
0
2
17
1
2
16
106
Investments
14
10
10
8
18
18
18
13
5
0
0
3
Other Assets
100
116
115
131
144
161
232
291
307
315
356
349
Total Assets
130
149
152
166
188
205
274
350
362
367
421
509
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
19
21
8
19
21
18
91
52
20
28
51
36
Investing
-5
1
0
-8
-11
-14
-88
-36
-2
19
-31
-21
Financing
-12
-11
-5
-9
-7
-12
-7
-17
-15
-48
-13
-14
Net Cash Flow
2
12
3
2
3
-7
-4
-1
3
-1
6
1
Free Cash Flow
13
20
5
18
19
16
89
29
11
21
15
-19
CFO/EBITDA
114
104
77
105
101
95
146
96
81
86
118
72
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
62
55
51
46
47
37
19
34
32
42
45
44
Inventory Days
44
44
44
40
45
74
45
53
58
50
45
56
Days Payable
46
51
110
102
92
98
106
122
95
96
113
106
Cash Conversion Cycle
61
48
-15
-16
0
13
-41
-35
-6
-5
-23
-6
Working Capital Days
42
45
76
26
30
70
28
92
117
173
99
94
ROCE %
26%
29%
28%
25%
25%
23%
44%
38%
19%
21%
22%
25%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Amrutanjan Health Care insights

70 extracted metrics + investor summaries across FY06–FY27.

Shareholding Pattern

FIIs3.47%Promot.46.52%DIIs6.90%Others7.59%Public35.53%As ofSep 2026

Documents

1
Concall - Aug 2026 Aug 2026
2
Concall - May 2026 May 2026
3
Concall - Feb 2026 Feb 2026
4
Concall - Feb 2026 Feb 2026
5
Concall - Nov 2025 Nov 2025

Frequently Asked Questions about Amrutanjan Health Care

What does Amrutanjan Health Care Ltd do?
AHCL has been manufacturing ayurvedic balm for pain management since 1893, and is currently managed by the third-generation of promoters. The company is more than 120 years old and is into OTC products in the segments of pain management, women's hygiene, and packaged fruit juice drink. [1]
Where is Amrutanjan Health Care Ltd (AMRUTANJAN) listed?
Amrutanjan Health Care Ltd trades as AMRUTANJAN on the NSE and under code 590006 on the BSE.
Which sector does Amrutanjan Health Care Ltd belong to?
Amrutanjan Health Care Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Amrutanjan Health Care Ltd?
Amrutanjan Health Care Ltd has a market capitalisation of ₹1,425 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Amrutanjan Health Care Ltd?
Amrutanjan Health Care Ltd trades at a PE ratio of 26.41 as of 28 Oct 2026, on earnings per share of ₹18.67, against a book value of ₹128.06 per share.
What is the 52-week high and low of Amrutanjan Health Care Ltd?
Over the last 52 weeks Amrutanjan Health Care Ltd has traded between ₹476.5 and ₹760.15 as of 28 Oct 2026.
Does Amrutanjan Health Care Ltd pay dividends?
Amrutanjan Health Care Ltd has a dividend yield of 1.00%.
What is the Return on Equity (ROE) of Amrutanjan Health Care Ltd?
Amrutanjan Health Care Ltd reported a return on equity of 18.92%. Its debt-to-equity ratio is 0.01.

Company Information

AHCL has been manufacturing ayurvedic balm for pain management since 1893, and is currently managed by the third-generation of promoters. The company is more than 120 years old and is into OTC products in the segments of pain management, women's hygiene, and packaged fruit juice drink. [1]

Website amrutanjan.com
CEO Mr. Sambhu Prasad Sivalenka
Employees 737
Listed 2015-01-02
Face Value ₹ 1
Shares Outstanding 2,89,10,630

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/AMRUTANJAN.md for Amrutanjan Health Care Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month